Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

BACKGROUND: Rituximab (Mabthera™) have been in use in India since 2000. A biosimilar molecule of rituximab (Reditux™) was approved in India in 2007. This retrospective audit was done to compare the efficacy and safety of Mabthera™ with Reditux™. MATERIALS AND METHODS: We reviewed the charts of 223 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Partha Sarathi, John, Shiji, Karankal, Sadashiv, Kannan, Sadhana, Pawaskar, Preeti, Gawande, Jayanta, Bagal, Bhausaheb, Khattry, Navin, Sengar, Manju, Menon, Hari, Gujral, Sumeet, Nair, Reena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932598/
https://www.ncbi.nlm.nih.gov/pubmed/24604960
http://dx.doi.org/10.4103/0971-5851.125248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932598/
https://www.ncbi.nlm.nih.gov/pubmed/24604960
http://dx.doi.org/10.4103/0971-5851.125248

Ejemplares similares